What We're Reading: Page 268
Industry reads hand-picked by our editors
Aug 16, 2018
Aug 15, 2018
Aug 14, 2018
Aug 13, 2018
-
The New York Times
Nebraska plans first execution in 21 years. Not so fast, drug company says.
-
The Wall Street Journal
China’s drugs problem spells opportunity for pharma giants
-
Reuters
Roundup cancer verdict sends Bayer shares sliding
Aug 10, 2018
-
Kaiser Health News
Trump administration sinks teeth into paring down drug prices, on 5 key points
-
Bloomberg
Red flags raised at Chinese heart drug maker year before recall
-
BioCentury
FDA rolls out guidance for seamless cancer trials
-
The Washington Post
Death reports make the opioid crisis personal for doctors
Aug 09, 2018
-
The Wall Street Journal
New Marijuana-Based Epilepsy Treatment to Cost $32,500 a Year
-
Bloomberg
The $250 Biohack That's Revolutionizing Life With Diabetes
-
MIT Technology Review
US scientist who edited human embryos with CRISPR responds to critics
Aug 08, 2018
-
Xconomy
With big Takeda deal at launch, can Ambys keep control of its future?
-
Bloomberg Opinion
Carl Icahn knows it's never too late to derail a deal
-
Boston Business Journal
As FDA decision looms, Alnylam triples Kendall footprint, plans to double staff
Previous
